BNP Paribas Asset Management’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
APM
RCM
FFM
VCM
OCA
TCM
BNP Paribas Asset Management's DNTH Position: Q1 2026 in Review
BNP Paribas Asset Management increased its Dianthus Therapeutics (DNTH) stake by 34% in Q1 2026, buying an estimated $4.29K and bringing the position to 290 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1971.
BNP Paribas Asset Management first reported a position in DNTH in Q4 2025 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.
- BNP Paribas Asset Management held 290 shares of Dianthus Therapeutics worth $24.3K as of Q1 2026.
- BNP Paribas Asset Management bought 74 Dianthus Therapeutics shares in Q1 2026, an estimated $4.29K.
- Dianthus Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1971 holding.
- BNP Paribas Asset Management first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 2 quarters since.
- 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.
Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.